Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald ...
"There is not enough research to support that anti-inflammatory foods or supplements such as vitamin C will make the COVID ...
The consensus analyst price target for Novavax stock has edged up from $12.50 to $13.21, reflecting an evolving outlook as the company navigates a transition in its business strategy. This shift ...
The French pharma’s overall vaccine sales declined 8% in the quarter, with a key driver being slower-than-usual uptake of flu ...
Many states have already announced their own Covid vaccine recommendations, creating "unprecedented" levels of confusion, one ...
According to the authors, vaccine effectiveness against infection reached 44.7% (95% confidence interval [CI], 37.7% to 50.9% ...
A troubled Indiana contract manufacturing plant recently acquired by Novo Nordisk is considered to not be in compliance with FDA standards ...
The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older. The Novavax vaccine is protein ...
NEW YORK (AP) — A more traditional kind of COVID-19 vaccine has moved a step closer to the U.S. market. Advisers to the Food and Drug Administration voted Tuesday to back shots made by Novavax for U.S ...
Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in ...
(Reuters) - Novavax Inc has begun a large late-stage study of its experimental COVID-19 vaccine in the United States, the drug developer said on Monday, after delaying the trial twice due to issues in ...
Oct 27 (Reuters) - Novavax Inc (NVAX.O), opens new tab on Tuesday delayed the start of a late-stage U.S. trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback